What is the typical presentation of hereditary hemorrhagic telangiectasia (HHT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Hereditary Hemorrhagic Telangiectasia: Clinical Presentation

HHT typically presents with recurrent spontaneous epistaxis (nosebleeds) occurring in over 90% of patients, along with characteristic mucocutaneous telangiectasias appearing as red spots on the lips, tongue, fingers, and nasal mucosa, plus visceral arteriovenous malformations affecting the lungs, liver, brain, and gastrointestinal tract 1, 2, 3.

Core Clinical Features

The presentation follows an age-related pattern of symptom expression 1:

Early Manifestations

  • Epistaxis begins in childhood and is nearly universal, with patients averaging up to 18 bleeds per month 4
  • Nosebleeds can last hours per day and cause significant psychosocial morbidity, social isolation, and employment difficulties 2
  • Most patients exhibit symptoms by age 60, with 97% penetrance 5

Progressive Features

  • Mucocutaneous telangiectasias develop over time on:

    • Lips and oral mucosa
    • Tongue
    • Fingers
    • Face
    • Nasal mucosa 1, 6
  • Visceral arteriovenous malformations in:

    • Lungs (pulmonary AVMs - can be catastrophic) 6
    • Liver (hepatic VMs)
    • Brain (cerebral AVMs)
    • Gastrointestinal tract (stomach and small bowel most common) 1, 6

Clinical Consequences

Bleeding-Related Complications

  • Iron deficiency anemia develops in nearly 50% of patients from chronic blood loss 3
  • Gastrointestinal bleeding ranges from minor to life-threatening 6
  • Chronic bleeding causes physical and emotional distress 7

Shunt-Related Complications

  • Complications from arteriovenous shunting through malformations 1
  • Pulmonary AVMs can lead to paradoxical emboli, stroke, or brain abscess
  • Hepatic VMs can cause high-output cardiac failure

Thrombotic Complications

  • Increased venous thromboembolism risk, particularly in patients over 65 years (incidence 45.1/1,000 patient-years vs 11.6/1,000 in younger patients) 8
  • Cerebral hemorrhage and thrombotic events increase morbidity and mortality 5

Diagnostic Criteria

Use the Curaçao criteria (upheld in international guidelines) 1:

  1. Spontaneous recurrent epistaxis
  2. Multiple telangiectasias at characteristic sites
  3. Visceral arteriovenous malformations
  4. First-degree family member with HHT

Definite diagnosis requires 3 of 4 criteria; possible diagnosis with 2 criteria 9.

Critical Pitfall: Atypical Presentations

Do not exclude HHT based solely on absence of epistaxis 5. While epistaxis occurs in >90% of cases, rare patients remain asymptomatic until late adulthood and present first with:

  • Spontaneous intracranial hemorrhage (subdural hematomas)
  • Unexplained gastrointestinal bleeding
  • Unexplained iron-deficiency anemia
  • Complications from visceral AVMs

One documented case showed a patient remaining asymptomatic until age 67, presenting with bilateral subdural hematomas and GI bleeding without prior epistaxis 5. Overreliance on classic mucocutaneous features contributes to diagnostic delay 5.

Genetic Basis

97% of patients with definite clinical diagnosis have identifiable mutations in 1:

  • ENG gene (HHT type 1)
  • ACVRL1 gene (HHT type 2)
  • SMAD4 gene (juvenile polyposis-HHT overlap syndrome)

Key Clinical Points

  • HHT is significantly underdiagnosed with long diagnostic delays 1
  • Prevalence is approximately 1 in 5,000 1, 2
  • Autosomal dominant inheritance pattern 1
  • Screen first-degree family members once diagnosis is established 6
  • Disease manifestations are more commonly associated with significant morbidity rather than mortality 4

Related Questions

In a patient with suspected hereditary hemorrhagic telangiectasia (HHT) in primary care, what are the next steps and appropriate referrals?
Could a person with facial, lip, and nasal telangiectasias that bleed rarely and a 2.9 cm inferior mesenteric venous varix (not an arteriovenous malformation) have hereditary hemorrhagic telangiectasia?
What causes epistaxis in hereditary hemorrhagic telangiectasia?
Can hereditary hemorrhagic telangiectasia cause a 2.9‑cm inferior mesenteric venous varix?
What is hereditary hemorrhagic telangiectasia (HHT)?
What is the recommended treatment protocol for drug‑resistant Hansen disease (leprosy)?
How should I manage a patient with mild-to-moderate left hydronephrosis due to suspected ureteropelvic junction obstruction, hazy urine with trace leukocyte esterase, and the laboratory findings provided?
In a 54-year-old man with type 2 diabetes mellitus, obesity (BMI 30) and hypertriglyceridemia (triglyceride level 5.1 mmol/L) who recently experienced pancreatitis, what is the best preventive strategy to prevent recurrent pancreatitis?
What is the recommended management for a patient with a tear of the body and posterior horn of the right medial meniscus, mild medial compartment osteoarthritis with small osteophytes, cartilage thinning and irregularity, and reactive marrow edema of the peripheral medial tibial plateau?
In a patient taking empagliflozin, metformin, and levothyroxine who began fluconazole every other day and now presents with clitoral pain and marked enlargement, could this be clitorodynia?
What is the appropriate treatment for a non‑displaced transverse fracture of the surgical neck of the humerus in a patient with moderate acromioclavicular joint arthritis and severe glenohumeral degenerative arthritis, with preserved glenohumeral joint alignment?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.